These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Yilmazer M; Fenkci V; Fenkci S; Sonmezer M; Aktepe O; Altindis M; Kurtay G Maturitas; 2003 Dec; 46(4):245-53. PubMed ID: 14625121 [TBL] [Abstract][Full Text] [Related]
3. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Prelevic GM; Kwong P; Byrne DJ; Jagroop IA; Ginsburg J; Mikhailidis DP Fertil Steril; 2002 May; 77(5):945-51. PubMed ID: 12009348 [TBL] [Abstract][Full Text] [Related]
4. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353 [TBL] [Abstract][Full Text] [Related]
5. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Cengiz B; Atabekoglu C; Cetinkaya E; Cengiz SD Maturitas; 2003 Dec; 46(4):301-6. PubMed ID: 14625127 [TBL] [Abstract][Full Text] [Related]
6. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W Fertil Steril; 2001 Mar; 75(3):554-9. PubMed ID: 11239541 [TBL] [Abstract][Full Text] [Related]
7. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Ylikorkala O; Cacciatore B; Paakkari I; Tikkanen MJ; Viinikka L; Toivonen J Fertil Steril; 1998 May; 69(5):883-8. PubMed ID: 9591497 [TBL] [Abstract][Full Text] [Related]
8. Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women. Zacharieva S; Atanassova I; Kirilov G; Kalinov K; Shigarminova R; Nachev E; Aslanova N Climacteric; 2002 Sep; 5(3):293-9. PubMed ID: 12419088 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281 [TBL] [Abstract][Full Text] [Related]
10. Continuous combined hormone replacement therapy compared with tibolone. Al-Azzawi F; Wahab M; Habiba M; Akkad A; Mason T Obstet Gynecol; 1999 Feb; 93(2):258-64. PubMed ID: 9932566 [TBL] [Abstract][Full Text] [Related]
11. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. Sumino H; Nakamura T; Ichikawa S; Kanda T; Sakamaki T; Sato K; Kobayashi I; Nagai R Atherosclerosis; 2000 Jan; 148(1):189-95. PubMed ID: 10580185 [TBL] [Abstract][Full Text] [Related]
12. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879 [TBL] [Abstract][Full Text] [Related]
13. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Prelevic GM; Bartram C; Wood J; Okolo S; Ginsburg J Gynecol Endocrinol; 1996 Dec; 10(6):413-20. PubMed ID: 9032569 [TBL] [Abstract][Full Text] [Related]
15. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women. Kurtay G; Ozmen B; Erguder I Maturitas; 2006 Jan; 53(1):32-8. PubMed ID: 16325022 [TBL] [Abstract][Full Text] [Related]
16. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201 [TBL] [Abstract][Full Text] [Related]
17. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143 [TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Suparto IH; Williams JK; Cline JM; Anthony MS; Fox JL Am J Obstet Gynecol; 2003 May; 188(5):1132-40. PubMed ID: 12748457 [TBL] [Abstract][Full Text] [Related]
19. [Basic principles of hormone replacement therapy in the postmenopause]. Dören M Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374 [TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I system and hormone replacement therapy. Cardim HJ; Lopes CM; Giannella-Neto D; da Fonseca AM; Pinotti JA Fertil Steril; 2001 Feb; 75(2):282-7. PubMed ID: 11172828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]